Cargando…

Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients

BACKGROUND: Our purpose was to investigate if dysregulation of cell adhesion molecules could be linked to prognosis in squamous cell carcinomas (SCCs) of the anal region. METHODS: Protein expression of desmoglein-1 (DSG1), desmocollin-1 (DSC1) and E-cadherin was studied by immunohistochemistry in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Myklebust, M P, Fluge, Ø, Immervoll, H, Skarstein, A, Balteskard, L, Bruland, O, Dahl, O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322941/
https://www.ncbi.nlm.nih.gov/pubmed/22333708
http://dx.doi.org/10.1038/bjc.2011.548
_version_ 1782229122743795712
author Myklebust, M P
Fluge, Ø
Immervoll, H
Skarstein, A
Balteskard, L
Bruland, O
Dahl, O
author_facet Myklebust, M P
Fluge, Ø
Immervoll, H
Skarstein, A
Balteskard, L
Bruland, O
Dahl, O
author_sort Myklebust, M P
collection PubMed
description BACKGROUND: Our purpose was to investigate if dysregulation of cell adhesion molecules could be linked to prognosis in squamous cell carcinomas (SCCs) of the anal region. METHODS: Protein expression of desmoglein-1 (DSG1), desmocollin-1 (DSC1) and E-cadherin was studied by immunohistochemistry in a cohort of 53 anal carcinoma patients treated by radiation alone or combined with 5-fluorouracil and mitomycin C. RESULTS: Univariate analyses identified, among others, negative membranous DSG1 staining (P=0.009), negative cytoplasmic DSC1 staining (P=0.012) and negative DSG1 (membranous)+negative DSC1 (cytoplasmic) staining (P=0.004) to be associated with improved cancer-specific survival (CSS). On multivariate analyses positive DSG1 (membranous)+DSC1 (cytoplasmic) staining (HR 6.95, P=0.044), large tumour size and lymph node metastases (HR 6.44, P=0.004) and radiation without chemotherapy (HR 6.73 P=0.004) were associated with worse CSS. On univariate analysis, improved disease-free survival was associated with negative membranous staining of DSG1 (P=0.047), and negative DSG1 (membranous)+negative DSC1 (cytoplasmic) staining (P=0.025), among others. CONCLUSION: Membrane negativity for DSG1 and cytoplasmic negativity for DSC1 are favourable markers for CSS in SCCs of the anal region.
format Online
Article
Text
id pubmed-3322941
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-33229412013-02-14 Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients Myklebust, M P Fluge, Ø Immervoll, H Skarstein, A Balteskard, L Bruland, O Dahl, O Br J Cancer Molecular Diagnostics BACKGROUND: Our purpose was to investigate if dysregulation of cell adhesion molecules could be linked to prognosis in squamous cell carcinomas (SCCs) of the anal region. METHODS: Protein expression of desmoglein-1 (DSG1), desmocollin-1 (DSC1) and E-cadherin was studied by immunohistochemistry in a cohort of 53 anal carcinoma patients treated by radiation alone or combined with 5-fluorouracil and mitomycin C. RESULTS: Univariate analyses identified, among others, negative membranous DSG1 staining (P=0.009), negative cytoplasmic DSC1 staining (P=0.012) and negative DSG1 (membranous)+negative DSC1 (cytoplasmic) staining (P=0.004) to be associated with improved cancer-specific survival (CSS). On multivariate analyses positive DSG1 (membranous)+DSC1 (cytoplasmic) staining (HR 6.95, P=0.044), large tumour size and lymph node metastases (HR 6.44, P=0.004) and radiation without chemotherapy (HR 6.73 P=0.004) were associated with worse CSS. On univariate analysis, improved disease-free survival was associated with negative membranous staining of DSG1 (P=0.047), and negative DSG1 (membranous)+negative DSC1 (cytoplasmic) staining (P=0.025), among others. CONCLUSION: Membrane negativity for DSG1 and cytoplasmic negativity for DSC1 are favourable markers for CSS in SCCs of the anal region. Nature Publishing Group 2012-02-14 2012-02-14 /pmc/articles/PMC3322941/ /pubmed/22333708 http://dx.doi.org/10.1038/bjc.2011.548 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular Diagnostics
Myklebust, M P
Fluge, Ø
Immervoll, H
Skarstein, A
Balteskard, L
Bruland, O
Dahl, O
Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients
title Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients
title_full Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients
title_fullStr Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients
title_full_unstemmed Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients
title_short Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients
title_sort expression of dsg1 and dsc1 are prognostic markers in anal carcinoma patients
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322941/
https://www.ncbi.nlm.nih.gov/pubmed/22333708
http://dx.doi.org/10.1038/bjc.2011.548
work_keys_str_mv AT myklebustmp expressionofdsg1anddsc1areprognosticmarkersinanalcarcinomapatients
AT flugeø expressionofdsg1anddsc1areprognosticmarkersinanalcarcinomapatients
AT immervollh expressionofdsg1anddsc1areprognosticmarkersinanalcarcinomapatients
AT skarsteina expressionofdsg1anddsc1areprognosticmarkersinanalcarcinomapatients
AT balteskardl expressionofdsg1anddsc1areprognosticmarkersinanalcarcinomapatients
AT brulando expressionofdsg1anddsc1areprognosticmarkersinanalcarcinomapatients
AT dahlo expressionofdsg1anddsc1areprognosticmarkersinanalcarcinomapatients